National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.
National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.
Drug Alcohol Depend. 2023 Oct 1;251:110940. doi: 10.1016/j.drugalcdep.2023.110940. Epub 2023 Aug 23.
What accounts for variation across racial and ethnic groups in drug use and harms related to substance use? While explanatory mechanisms for racial and ethnic disparities include differential access to and use of health services, a myriad of other factors, including racism and historical trauma, contribute to drug-related disparities. Furthermore, the addiction scientific workforce, like the full biomedical research enterprise, lacks diversity. This deficit undercuts U.S. scientific leadership and is a major challenge for the field. To address these entrenched problems, the National Institute on Drug Abuse (NIDA) is prioritizing research on health disparities and supporting multiple efforts to enhance scientific workforce diversity. Studies on substance use trends and emerging threats must measure disparities and track progress in reducing disparities, but also acknowledge the limitations of race and ethnicity-based data. Researchers must take the bold step of proposing studies that elucidate causal mechanisms which have the potential to be ameliorated by novel policies and practices. Critically, the impact of racism on all aspects of the substance use trajectory must be assessed to better tailor prevention, harm reduction, treatment, and recovery-support interventions to the specific circumstances of those who need them. Particular attention should be given to people who are incarcerated, who are experiencing homelessness, and who have a history of adverse childhood experiences. Training the next generation of the addiction science workforce needs to address structural barriers to participation with partnerships between funders, such as NIDA, and grantee organizations.
是什么导致了不同种族和族裔群体在药物使用和与物质使用相关的危害方面存在差异?虽然导致种族和族裔差异的解释机制包括获得和使用卫生服务的差异,但还有许多其他因素,包括种族主义和历史创伤,导致了与毒品相关的差异。此外,成瘾科学工作者队伍,就像整个生物医学研究企业一样,缺乏多样性。这种不足削弱了美国的科学领导力,也是该领域的主要挑战。为了解决这些根深蒂固的问题,国家药物滥用研究所 (NIDA) 正在优先研究健康差异,并支持多项努力来增强科学工作者队伍的多样性。关于物质使用趋势和新出现威胁的研究必须衡量差异,并跟踪减少差异的进展,但也要认识到基于种族和族裔的数据存在局限性。研究人员必须大胆提出研究,阐明潜在机制,这些潜在机制有可能通过新政策和实践得到改善。至关重要的是,必须评估种族主义对药物使用轨迹各个方面的影响,以便更好地针对那些需要预防、减少伤害、治疗和康复支持的人量身定制预防、减少伤害、治疗和康复支持干预措施。特别应该关注那些被监禁、无家可归或有不良童年经历的人。培养下一代成瘾科学工作者队伍需要解决参与的结构性障碍,资助者(如 NIDA)与受赠组织之间建立伙伴关系。